Zanzalintinib

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our pipeline of franchise molecules, including our novel oral kinase inhibitor zanzalintinib, and to extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Exelixis , the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis, Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527998005/en/ Investors Contact: Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@torchcomllc.com Source: Exelixis, Inc.

Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer trial. California-based Exelixis partnered with Natera on the trial in January. Natera is providing its molecular residual disease (MRD) test for use in the study, as it did for a Roche trial that supported a recent label expansion for Tecentriq. Echoing Roche’s strategy in a different indication, Exelixis will enroll patients with resected colorectal cancer who test positive for MRD but have no radiographic evidence of disease. At the time of the Natera news, Exelixis said that patients who meet the enrollment criteria will receive zanzalintinib, its multitargeted tyrosine-kinase inhibitor, with or without an immune checkpoint inhibitor. Tuesday’s update revealed the identity of the immune checkpoint inhibitor. Merck has agreed to supply Keytruda Qlex, the subcutaneous version of its blockbuster PD-1 inhibitor. The companies have a preexisting relationship, with Merck providing Keytruda for Exelixis’ phase 3 head and neck cancer trial under a 2024 agreement. But Exelixis’ previous work in colorectal cancer paired zanzalintinib with Roche’s Tecentriq. Exelixis has filed for FDA approval of the zanzalintinib-Tecentriq combination in a pretreated, metastatic colorectal cancer patient population, with the agency set to reach a decision by Dec. 3. Clinical data on the combination in metastatic colorectal cancer informed the decision to start the MRD trial, Exelixis CEO Michael Morrissey, Ph.D., said at a Bank of America event last week. “If zanza plus a checkpoint was effective at improving survival for patients with radiographic tumors, a large enough tumor mass where you could see it on an MRI or CT scan, then going after micrometastases with the same approach was a pretty good bet,” Morrissey said at the event. Last year, researchers presented phase 3 data on Taiho Oncology’s Lonsurf in a similar patient population to that targeted in Exelixis’ planned study. Median disease-free survival was 9.3 months on the oral chemotherapy combination, compared with 5.5 months in the control cohort. Exelixis’ decision to target the patient population was informed more by its metastatic data than rivals’ results, Morrissey said. Exelixis expects to start the study in mid-2026. Success could establish zanzalintinib, either with or without Keytruda, as a treatment for cancer patients who lack good options. The high-risk post-adjuvant population “is truly high risk,” Morrissey said, with some patients progressing within five months of their last round of adjuvant chemotherapy. The content above comes from the network. if any infringement, please contact us to modify.